Sulforafan alfadex

N/A

Report date: 2025/07/01 15:17:14

Base Information

Drug NameSulforafan alfadex
Drug Alias NameSulphoraphane-alfadex磺胺葡聚糖Stabilised sulforaphaneSulforafan-alpha-cyclodextrinSulforaphane-alphacyclodextrin +[12] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionHistone deacetylase inhibitorsNuclear factor erythroid 2-related factor 2 stimulantsWingless type MMTV integration site family protein modulators +[6] 
TargetsNuclear factor erythroid 2-related factor 2Androgen ReceptorWingless type MMTV integration site family protein +[5] 
Therapy Area/IndicationsNasolabial fold wrinklesSchizophreniaAutistic Disorder +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPharmagra Labs IncLalilabEvgen Pharma
China Registration ClassN/A

Develop Information

Active CompaniesStalicla SaNational Institutes Of HealthUniversity Of Rochester +[8] 
Inactive CompaniesEvgen PharmaOhsu Knight Cancer InstituteThe University Of Arizona +[6] 
Active IndicationsNasolabial fold wrinklesSchizophreniaAutistic Disorder +[12] 
Inactive IndicationsNeurodevelopmental DisordersDrug-Related Side Effects and Adverse ReactionsHyperplasia +[12] 

Other Information

ATC CodeN/A
Related LinksN/A